# US 2026/0242346 A1 · Lipid compounds, compositions, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242346 A1
- Document ID: US20260242346A1
- Status: Published application
- Kind: A1
- Application number: 19/419,500
- Filed: 2025-12-15
- Published: 2026-08-20
- Earliest claimed: 2023-05-30
- Assignees: Liberate Bio, Inc.
- Applicants: Liberate Bio, Inc.
- Inventors: Gregory Lawrence HAMILTON; Can SARISOZEN; Parminder Kaur MANKOO; Stephen S. SCULLY
- Web page: https://patentgrep.com/patent/US20260242346A1

## CPC

- C07D 295/13: to an acyclic saturated chain
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/6911: {the form being a liposome}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- C07C 271/20: to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/62: attached in position 4
- C07D 309/06: Radicals substituted by oxygen atoms
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 493/08: Bridged systems
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).

## Claims

### Claim at position 1

1-121. (canceled)

### Claim 122

A compound of the following formula:
or a pharmaceutically acceptable salt thereof; wherein:
each of R1 and R1′ is independently (C1-C9 alkyl)-R5;
R1″ is (C1-C9 alkyl)-R5 or an optionally substituted C3-C12 cycloalkyl;
each R5 is independently hydrogen, optionally substituted C3-C12 cycloalkyl, or C(O)O—R6;
each R6 is independently C7-C12 alkenyl;
R2 is C1-C12 alkyl;
R3 and R4 join together to form a heterocyclic ring comprising one or more N atoms; and
p is 0 or 2.

### Claim 123 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein each of R1 and R1′ is independently (C1-C9 alkyl)-R5 and each R5 is independently C(O)O—R6.

### Claim 124 (depends on 123)

The compound or pharmaceutically acceptable salt of claim 123, wherein R6 is C9 alkenyl.

### Claim 125 (depends on 124)

The compound or pharmaceutically acceptable salt of claim 124, wherein R1 and R1′ are

### Claim 126 (depends on 124)

The compound or pharmaceutically acceptable salt of claim 124, wherein R1 and R1′ are

### Claim 127 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein R1″ is (C1-C9 alkyl)-R5 and R5 is hydrogen.

### Claim 128 (depends on 127)

The compound or pharmaceutically acceptable salt of claim 127, wherein R1″ is n-pentyl.

### Claim 129 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein R1″ is (C1-C9 alkyl)-R5 and R5 is unsubstituted C10 cycloalkyl.

### Claim 130 (depends on 129)

The compound or pharmaceutically acceptable salt of claim 129, wherein R1″ is (C1 alkyl)-R5 and R5 is 1-adamantyl.

### Claim 131 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein R1″ is an optionally substituted C3-C12 cycloalkyl.

### Claim 132 (depends on 131)

The compound or pharmaceutically acceptable salt of claim 131, wherein R1″ is

### Claim 133 (depends on 131)

The compound or pharmaceutically acceptable salt of claim 131, wherein R1″ is

### Claim 134 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein R2 is n-hexyl.

### Claim 135 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein R2 is n-butyl.

### Claim 136 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein R3 and R4 join together to form

### Claim 137 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein p is 0.

### Claim 138 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein p is 2.

### Claim 139 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 140 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 141 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 142 (depends on 122)

The compound or pharmaceutically acceptable salt of claim 122, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 143 (depends on 122)

A lipid nanoparticle comprising the compound or pharmaceutically acceptable salt of claim 122.

### Claim 144 (depends on 143)

The lipid nanoparticle of claim 143, wherein the compound or pharmaceutically acceptable salt is
or a pharmaceutically acceptable salt thereof.

### Claim 145 (depends on 143)

The lipid nanoparticle of claim 143, further comprising a targeting component selected from a targeting lipid and an active targeting component, wherein the active targeting component is a protein, a peptide, a small molecule, or an antibody or antigen-binding fragment thereof.

### Claim 146 (depends on 143)

The lipid nanoparticle of claim 143, further comprising one or more polynucleotides encapsulated within the lipid nanoparticle.

### Claim 147 (depends on 143)

A pharmaceutical composition comprising the lipid nanoparticle of claim 143, and a pharmaceutically acceptable excipient.

### Claim 148 (depends on 147)

A pharmaceutical composition comprising the lipid nanoparticle of claim 147, and a pharmaceutically acceptable excipient.

### Claim 149 (depends on 146)

A method of delivering one or more polynucleotides to an extrahepatic cell or tissue in a subject, comprising administering to the subject an effective amount of the lipid nanoparticle of claim 146.

### Claim 150 (depends on 149)

The method of claim 149, wherein the compound or pharmaceutically acceptable salt is
or a pharmaceutically acceptable salt thereof.
